NAV

Peginterferon alfa-2a

Identification

Summary

Peginterferon alfa-2ais a modified form of recombinant human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C viruses.

Brand Names
Pegasys
Generic Name
Peginterferon alfa-2a
DrugBank Accession Number
DB00008
Background

Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients3。Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2a. Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of Peginterferon alfa-2a is associated with a wide range of severe adverse effects including the aggravation and development of endocrine and autoimmune disorders, retinopathies, cardiovascular and neuropsychiatric complications, and increased risk of hepatic decompensation in patients with cirrhosis. The use of Peginterferon alfa-2a has largely declined since newer interferon-free antiviral therapies have been developed.

In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) no longer recommend Peginterferon alfa-2a for the treatment of Hepatitis C1。Peginterferon alfa-2a was used alongsideRibavirinwith the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality2。

Peginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C. Approved in 2002 by the FDA, Pegasys is indicated for the treatment of HCV withRibavirinor other antiviral drugsLabel。When combined together, Peginterferon alfa-2a andRibavirinhave been shown to achieve a SVR between 36% for genotype 1 and 59% for genotypes 2-6 after 48 weeks of treatment.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
蛋白质Based Therapies
Interferons
蛋白质Structure
蛋白质Chemical Formula
Not Available
蛋白质Average Weight
60000.0 Da
Sequences
>Peginterferon alfa-2a sequence CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
Download FASTA Format
Synonyms
  • PEG-IFN alfa-2A
  • PEG-Interferon alfa-2A
  • Peginterferon alfa-2a
  • Pegylated Interfeaon alfa-2A
  • Pegylated interferon alfa-2a
  • Pegylated interferon alpha-2a
  • Pegylated-interferon alfa 2a
External IDs
  • RO 25-8310/000
  • RO-25-8310/000
  • RO-258310000

Pharmacology

Indication

Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver diseaseLabel。May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.

Peginterferon alfa-2a is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have compensated liver disease and evidence of viral replication and liver inflammationLabel。

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Peginterferon alfa-2a induces the body's innate antiviral responseLabel。

Mechanism of action

Peginterferon alfa-2a is derived from recombinant human interferon's alfa-2a moeityLabel。It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway. Activation of the JAK/STAT pathway increases expression of multiple genes in multiple tissues involved in the innate antiviral response.

Target Actions Organism
AInterferon alpha/beta receptor 2
agonist
 Humans
AInterferon alpha/beta receptor 1
agonist
 Humans
吸收

Peginterferon alfa-2a reaches peak plasma concentration 72-96 hours after subcutaneous administrationLabel。Trough concentrations at week 48 are approximately 2 fold higher than week 1. The peak to trough ratio at week 48 is 2.

Volume of distribution

Not Available

蛋白质binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

半衰期

The mean terminal half-life of peginterferon alfa-2a is 164 in a range of 84-353 hoursLabel。

Clearance

The mean systemic clearance of peginterferon alfa-2a is 94 milliliters per hourLabel。

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Peginterferon alfa-2a may manifest neuropsychiatric complications include suicide, suicidal ideation, homicidal ideation, depression, relapse of drug addiction, and drug overdoseLabel。混身起红疹;痒高血压、室上性心律失常t pain, and myocardial infarction have been observed in patients using Peginterferon alfa-2a. Peginterferon alfa-2a may produce myelosuppression as well as the development or aggravation of autoimmune disorders including myositis, hepatitis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, interstitial nephritis, thyroiditis, and systemic lupus erythematosus. Peginterferon alfa-2a causes or aggravates hypothyroidism and hyperthyroidism. Hyperglycemia, hypoglycemia, and diabetes mellitus have been observed to develop in patients treated with Peginterferon alfa-2a. Peginterferon alfa-2a may decrease or produce loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema and serous retinal detachment. Peginterferon mayy be related to increased ischemic and hemorrhagic cerebrovascular events. Patients with cirrhosis on Peginterferon alfa-2a are at risk of hepatic decompensation. Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension and sarcoidosis may be induced or aggravated by Peginterferon alfa-2a. Serious and severe infections (bacterial, viral, or fungal) have been reported during treatment with Peginterferon alfa-2a. Ulcerative and hemorrhagic/ischemic colitis have been observed within 12 weeks of starting Peginterferon alfa-2a treatment. Pancreatitis and peripheral nephropathy have also been reported. Peginterferon alfa-2a is associated with growth inhibition in pediatric patients. Use of Peginterferon alfa-2a while pregant may result in delopmental abnormalities or death of the fetus.

Pathways
Not Available
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details
Interferon lambda-3 --- (C;T)/(G;G)/(G, T)/(T;T) C > T EffectDirectly Studied Patients with this genotype in IFNL3 have a reduced likelihood of achieving sustained virologic response to peginterferon alfa-2a therapy. Details

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction
整合药物之间
interactions in your software
Abatacept The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Abatacept.
Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Peginterferon alfa-2a.
Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Peginterferon alfa-2a.
Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Peginterferon alfa-2a.
Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Peginterferon alfa-2a.
Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Peginterferon alfa-2a.
Acyclovir The metabolism of Acyclovir can be decreased when combined with Peginterferon alfa-2a.
Adalimumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Adalimumab.
Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Peginterferon alfa-2a.
Agomelatine The metabolism of Agomelatine can be decreased when combined with Peginterferon alfa-2a.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Drink plenty of fluids.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
品牌名称的处方产品
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image
Pegasys Injection, solution 135 μg Subcutaneous Zr Pharma& Gmb H 2016-09-08 Not applicable EU flag
Pegasys Injection, solution 180 μg Subcutaneous Zr Pharma& Gmb H 2016-09-08 Not applicable EU flag
Pegasys Injection, solution 180 ug/1mL Subcutaneous Zr Pharma& Gmbh 2002-10-16 Not applicable US flag
Pegasys Injection, solution 135 μg Subcutaneous Zr Pharma& Gmb H 2016-09-08 Not applicable EU flag
Pegasys Injection, solution 180 μg Subcutaneous Zr Pharma& Gmb H 2016-09-08 Not applicable EU flag
Pegasys Injection, solution 180 ug/0.5mL Subcutaneous Roche Pharmaceuticals 2007-12-04 2007-12-04 US flag
Pegasys Injection, solution 180 ug/0.5mL Subcutaneous Genentech, Inc. 2011-11-01 Not applicable US flag
Pegasys Injection, solution 180 μg Subcutaneous Zr Pharma& Gmb H 2016-09-08 Not applicable EU flag
Pegasys Injection, solution 180 μg Subcutaneous Zr Pharma& Gmb H 2016-09-08 Not applicable EU flag
Pegasys Injection, solution 180 μg Subcutaneous Zr Pharma& Gmb H 2016-09-08 Not applicable EU flag
Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image
Pegasys Rbv Peginterferon alfa-2a(180 mcg / 0.5 mL)+Ribavirin(200 mg / tab) Solution; Tablet Oral; Subcutaneous Hoffmann La Roche 2004-05-26 2018-07-10 Canada flag
Pegasys Rbv Peginterferon alfa-2a(180 mcg / mL)+Ribavirin(200 mg / tab) Solution; Tablet Oral; Subcutaneous Hoffmann La Roche 2004-05-26 2018-07-10 Canada flag

Categories

ATC Codes
L03AB11 — Peginterferon alfa-2a L03AB61 — Peginterferon alfa-2a, combinations
Drug Categories
Chemical TaxonomyProvided byClassyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
Q46947FE7K
CAS number
198153-51-4

References

一般引用
  1. Bagaglio S, Uberti-Foppa C, Morsica G: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs. 2017 May 12. doi: 10.1007/s40265-017-0753-x. [Article]
  2. Myers RP, Shah H, Burak KW, Cooper C, Feld JJ: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. Epub 2015 Jan 13. [Article]
  3. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017. [Link]
UniProt
P01563
Genbank
J00207
PubChem Substance
46504860
RxNav
120608
ChEMBL
CHEMBL1201560
Therapeutic Targets Database
DAP001278
PharmGKB
PA164749390
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Peginterferon_alfa-2a
FDA label
Download (1.13 MB)

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
4 Active Not Recruiting Treatment Viral Hepatitis B 1
4 Completed Not Available Hepatitis B Chronic Infection 1
4 Completed Basic Science Chronic Hepatitis C Virus (HCV) Infection/Liver Disease/Viral Disease 1
4 Completed Diagnostic Chronic Hepatitis C Virus (HCV) Infection 1
4 Completed Prevention Hepatitis B Chronic Infection 1
4 Completed Prevention Hepatitis C Virus (HCV) Infection/Liver Transplantation 1
4 Completed Treatment Anemia 1
4 Completed Treatment Antiviral Agents/Chronic Liver Diseases (CLD)/Hepatitis C Virus (HCV) Infection/Therapeutic Uses/Virus Hepatitis 1
4 Completed Treatment Asian Americans/Chronic Hepatitis C Virus (HCV) Infection/Novel Genotypes/Treatments 1
4 Completed Treatment Chronic Hepatitis C Genotype 1 2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • F Hoffmann La Roche Ltd.
  • F Hoffmann-La Roche Ltd.
剂型
Form Route Strength
Injection Subcutaneous
Injection, solution Subcutaneous 135 μg
Injection, solution Subcutaneous 135 MCG
Injection, solution Subcutaneous 135 ug/0.5mL
Injection, solution Subcutaneous 180 mcg/ml
Injection, solution Subcutaneous 180 μg
Injection, solution Subcutaneous 180 ug/1mL
Injection, solution Subcutaneous 180 MCG
Injection, solution Subcutaneous 180 ug/0.5mL
Injection, solution Subcutaneous 90 μg
Solution Subcutaneous 180 mcg / 0.5 mL
Solution Subcutaneous 180 mcg / mL
Injection, solution Subcutaneous
Injection Subcutaneous 135 mcg/0.5ml
Injection Subcutaneous 180 mcg/0.5ml
Solution; tablet Oral; Subcutaneous
Injection, solution Subcutaneous 135 mcg/0.5ml
Injection, solution Subcutaneous 180 mcg/0.5ml
Prices
Unit description Cost Unit
Pegasys (1 Kit = Four 180 mcg/ml Vials Prefilled Syringes) Box 2634.53USD box
Pegasys 180 mcg/0.5 ml conv.pk 2533.2USD each
Pegasys 180 mcg/ml vial 642.64USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region
CA2172664 No 2000-10-03 2016-03-26 Canada flag
CA2203480 No 2009-06-30 2017-04-23 Canada flag

Properties

State
Liquid
Experimental Properties
Property Value 源
melting point (°C) 61 °C Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)
isoelectric point 5.99 Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets tounlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details 1.Interferon alpha/beta receptor 2
Kind
蛋白质
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Type i interferon receptor activity
Specific Function
Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are direc...
Gene Name
IFNAR2
Uniprot ID
P48551
Uniprot Name
Interferon alpha/beta receptor 2
分子量
57758.24 Da
References
  1. Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. [Article]
  2. Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. [Article]
  3. Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3. [Article]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Details 2.Interferon alpha/beta receptor 1
Kind
蛋白质
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Type i interferon receptor activity
Specific Function
Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JA...
Gene Name
IFNAR1
Uniprot ID
P17181
Uniprot Name
Interferon alpha/beta receptor 1
分子量
63524.81 Da
References
  1. Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. [Article]
  2. Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. [Article]
  3. Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3. [Article]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]

Enzymes

Details 1.Cytochrome P450 1A2
Kind
蛋白质
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
分子量
58293.76 Da
References
  1. Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, Kosel M, Baumann P, Eap CB: Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol. 2002 Apr;22(2):211-5. [Article]
  2. Peg-interferon FDA label [File]

Drug created at June 13, 2005 13:24 / Updated at April 11, 2023 21:33